Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036556 · ClinicalTrials.gov registry record · Phase 3
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 941
- Enrollment target
NCT00036556: Completed Phase 3 study, sponsored by Abbott.
NCT00036556 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 941 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036556, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 941 participants
- Enrollment target
Study Summary
This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
Interventions
- DRUG Atrasentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 941 participants |
| Start Date | 2001-06 |
| Phase | Phase 3 |
What the finished NCT00036556 record still lists
NCT00036556 is an interventional study that assigns participants to a tested intervention. The registered 941 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 1 intervention - of which Atrasentan is the first listed.
NCT00036556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036556 about?
NCT00036556 is a clinical study titled "Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer". This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
What is the current status of trial NCT00036556?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 941 participants. The study started on 2001-06.
What interventions are being tested in trial NCT00036556?
The interventions under investigation include: Atrasentan (DRUG).
Who is sponsoring clinical trial NCT00036556?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00036556's enrollment target sits among peer trials
941 337th of 2000 higher than 1,664 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia